TRT and GLP-1 Medications: What Men on Ozempic, Wegovy, and Mounjaro Need to Know

If you're on testosterone replacement therapy and your doctor just suggested Ozempic, or if you've been losing weight on a GLP-1 medication and now feel like your T levels have shifted, you're encountering one of the most actively researched intersections in men's health right now. The data is new, it's interesting, and it matters for your treatment plan.

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), dulaglutide (Trulicity) — were developed for diabetes and obesity. But a growing body of research shows they affect testosterone levels, body composition, and fertility in men who also need to think about hormone replacement. Here's what we know as of 2026.

The Key Finding: GLP-1s Can Boost Testosterone — Indirectly

At the Endocrine Society's 2025 annual meeting, researchers presented a study of 110 men (average age 54) with obesity and type 2 diabetes who were treated with semaglutide, dulaglutide, or tirzepatide — none received concurrent testosterone therapy. Over 18 months, the men lost an average of 10% of body weight and saw total testosterone increase by 53% to 77%. Free testosterone rose similarly.

Dr. Shellsea Portillo Canales, the study's lead author from SSM Health St. Louis University Hospital, noted: "While it is well known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied. Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications."

Key point: semaglutide does not directly stimulate testosterone production. The increase is mediated through weight loss. Obesity suppresses testosterone through multiple mechanisms — disrupted luteinizing hormone signaling from the pituitary, elevated leptin reducing testicular cell activity, and increased peripheral conversion of testosterone to estrogen via aromatase in adipose tissue. Remove enough fat mass, and some of that suppression lifts.

What This Means for Men Already on TRT

If you're receiving testosterone replacement and start a GLP-1 medication, several things could happen:

Your T levels may rise above your current target range. If you're on a fixed-dose TRT protocol and lose significant weight, your endogenous testosterone production may partially recover while you're still receiving exogenous testosterone. This could push your total testosterone higher than intended. Regular monitoring — not guesswork — is essential.

Your body composition improvements may accelerate. GLP-1s reduce appetite and caloric intake. TRT preserves lean muscle during caloric deficits. The combination is increasingly viewed by metabolic medicine clinicians as synergistic — fat loss from the GLP-1, muscle preservation from TRT.

A 2025 narrative review published in Cureus examined this exact question: can TRT preserve lean mass in men with persistently low testosterone who are receiving GLP-1 receptor agonists? The review concluded that TRT may serve as an effective strategy to prevent the muscle loss that typically accompanies GLP-1–induced weight reduction — a concern because losing muscle lowers resting metabolic rate and makes long-term weight maintenance more difficult.

Fertility: A Critical Distinction Between GLP-1s and TRT

TRT suppresses the hypothalamic-pituitary-gonadal axis. When you introduce exogenous testosterone, your brain reduces LH and FSH production, which signals the testes to slow or stop sperm production. This is why men pursuing fertility are often prescribed hCG alongside or instead of TRT.

GLP-1 medications appear to have the opposite effect. A 2025 systematic review covering 371 men across 7 studies found that GLP-1 receptor agonists were associated with improvements in sperm count, motility, and morphology — particularly in men with obesity and metabolic dysfunction. One 2024 study found that men with baseline sperm parameters in the bottom 5% saw a 2% increase in normally shaped sperm after 24 weeks of semaglutide, and the semaglutide group outperformed the TRT group in sperm concentration and total count.

For men who want to lose weight and protect fertility simultaneously, GLP-1s may offer advantages that TRT does not. That doesn't mean TRT is wrong for you — but it's a conversation worth having with your prescribing clinician.

The ED Signal in the Data

Not all findings favor GLP-1s. A 2024 study of over 3,000 obese, non-diabetic men found that semaglutide users showed higher rates of erectile dysfunction (1.47% vs. 0.32% in controls) and new diagnoses of low testosterone (1.53% vs. 0.80%). The absolute rates are low, and the researchers noted that correlation does not equal causation — confounding variables may explain the increased rates. But the signal exists, and it's worth discussing with your doctor if sexual function is a primary reason for pursuing TRT.

Who Is the Ideal Candidate for Combined Therapy?

The men who may benefit most from coordinated TRT and GLP-1 therapy typically present with:

• Documented low testosterone below 300 ng/dL with symptomatic presentation
• BMI above 27 with overweight or obesity
• Impaired glucose metabolism or established type 2 diabetes
• History of muscle loss during prior weight loss attempts
• Desire to improve both metabolic and hormonal health markers

Contraindications exist for both therapies. TRT should not be used in men with active prostate cancer, severe untreated sleep apnea, or uncontrolled heart failure. GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Monitoring Protocol for Combined Therapy

If you and your physician decide to pursue both therapies, expect quarterly lab monitoring during the initiation phase, transitioning to semi-annual monitoring once stable. Tracked parameters typically include total and free testosterone, LH, FSH, estradiol, hematocrit, fasting glucose, HbA1c, lipid panel, and liver function tests. Your clinician may adjust TRT dosing as weight loss progresses and endogenous hormone production changes.

Bottom Line

GLP-1 medications can meaningfully improve testosterone levels in men with obesity through weight loss — but they don't directly stimulate testosterone production. For men already on TRT, the combination may accelerate body composition improvements if managed carefully by a physician. For men concerned about fertility, GLP-1s may offer weight loss benefits without the gonadal suppression that TRT causes. Either way, this is not self-manageable territory. Both therapies affect hormone axes, metabolic pathways, and cardiovascular risk factors. Coordinate with your prescribing clinician, get labs, and adjust based on data — not symptoms alone.